8-K: NeOnc Expands Middle East Presence with Key Clinical Trial Partnership

NeOnc Technologies' UAE subsidiary, NuroMENA, has signed a Master Services Agreement with IROS, an M42 affiliate, to accelerate clinical trials for CNS therapies in the Middle East, concurrently expanding its board with Quazar Investment partners.

Summary

• NeOnc Technologies Holdings, Inc. (NTHI) announced two strategic developments for its Middle East expansion.
• Its wholly-owned UAE subsidiary, NuroMENA Holdings Ltd., entered into a Master Services Agreement (MSA) with Insights Pharmaceutical Research LLC (IROS), a UAE-based contract research organization and an affiliate of Group 42 Holding Ltd. and Mubadala Investment Company PJSC.
• The MSA outlines terms for IROS to provide clinical research services for NeOnc's clinical development programs in the UAE, including regulatory submissions, site selection, clinical monitoring, data management, and trial reporting.
• The first work order under the MSA is for a multi-site, randomized Phase 2b/3 study evaluating Intranasal NEO100 in patients with progressive or recurrent Grade III Astrocytomas and Glioblastoma Multiforme (GBM).
• This initial work order has an estimated budget of approximately $2.4 million in service fees and $0.1 million in pass-through costs, payable in four milestone-based installments.
• NeOnc retains all rights to clinical data, intellectual property, and regulatory filings from studies under the MSA.
• The NuroMENA Board of Directors is expanding to include Waleed K. Al Ali, CEO of Quazar Investment, and the Chairman of Quazar Investment, alongside existing directors Amir Heshmatpour, Dr. Ishwar K. Puri, and Bader Al Monawer.
• NuroMENA was officially incorporated under ADGM on August 6, 2025.

Sentiment

Score: 8

Explanation: The filing announces a significant strategic partnership with a well-regarded entity (IROS, part of M42) in a growing healthcare market (UAE), coupled with a board expansion that strengthens governance and regional focus. This is a strong positive development for a clinical-stage company, providing infrastructure and validation. The reference to a $50 million investment further underpins financial stability for the regional subsidiary.

Positives

• Secured access to a world-class health ecosystem and advanced healthcare infrastructure in the UAE through partnership with IROS, an M42 entity.
• The partnership is expected to accelerate clinical development of NeOnc's innovative cancer therapies, particularly for central nervous system (CNS) cancers.
• The association with an M42 entity provides strong validation of NeOnc's scientific platform.
• Expansion of NuroMENA's Board of Directors with key partners from Quazar Investment establishes a strong leadership team for regional strategy and growth.
• The Master Services Agreement ensures NeOnc retains all rights to clinical data, intellectual property, and regulatory filings.
• The initial work order targets a significant unmet medical need (Grade III Astrocytomas and Glioblastoma Multiforme) with a Phase 2b/3 study for NEO100.

Risks

• Inherent uncertainty of clinical trial results, with no assurance that the Study Drug will be approved and/or successfully marketed.
• Potential failure to finalize the broader $50 million investment agreement with Quazar Investment.
• Possible modifications to the terms of the Quazar investment agreement.
• Alternative uses of proceeds from the Quazar investment could impact strategic plans.
• Delays in clinical trial performance due to actions or omissions of governmental entities, regulatory or external ethics committee encumbrance, or study enrollment issues.
• Delays or failures by the Client (NeOnc) to perform its obligations under the MSA or Clinical Trial Agreement.
• Force Majeure events could delay or prevent performance of obligations.
• Financial difficulty is explicitly stated as not being a Force Majeure event, implying it remains a risk.

Future Outlook

The company anticipates accelerating its mission to bring novel cancer treatments to patients, leveraging the elite infrastructure provided by IROS and the strategic leadership from the expanded NuroMENA board. The partnership aims to fast-track clinical trials and position Abu Dhabi as a global hub for clinical excellence and innovation in oncology. The company's NEO100 and NEO212 therapeutics are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status.

Management Comments

• "Signing an agreement with IROS, an entity backed by a global force like M42, is a transformative event. This MSA provides the elite infrastructure needed to fast-track our clinical trials. By simultaneously installing a powerful board with our partners at Quazar, we are establishing a premier foundation for both operational excellence and strategic leadership in the Middle East. Together, these actions will dramatically accelerate our mission to bring novel cancer treatments to patients." Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies.
• "At IROS, we are proud to provide the platform, infrastructure and expertise that enable companies like NeOnc to accelerate the development of breakthrough cancer therapies. Through Abu Dhabis world-class health ecosystem that is fully aligned with international standards, we are able to conduct clinical trials with exceptional speed, quality and integrity. This partnership reflects our shared commitment to advancing research that brings new hope to patients and positions Abu Dhabi as a global hub for clinical excellence and innovation in oncology." Islam Eltantawy, General Manager at IROS.

Industry Context

This announcement aligns with broader trends in the biopharmaceutical industry towards globalizing clinical trials, particularly leveraging emerging healthcare hubs like the UAE. The partnership with M42, a global health company powered by AI, technology, and genomics, highlights the increasing integration of advanced technology and data-driven approaches in clinical research. It also reflects a strategic move by NeOnc to access diverse patient populations and potentially more efficient regulatory pathways in new territories, while M42/IROS aims to position Abu Dhabi as a leader in clinical excellence and oncology innovation.

Comparison to Industry Standards

• The filing emphasizes that IROS operates within Abu Dhabi's "world-class health ecosystem that is fully aligned with international standards" and conducts clinical trials with "exceptional speed, quality and integrity."
• The association with M42, a global health champion powered by AI, technology, and genomics, suggests a high standard of operational and technological capability in clinical research.
• The inclusion of FDA regulations (21 CFR Parts 50 and 56) in the exhibit indicates adherence to stringent international clinical trial guidelines, which is a benchmark for quality and regulatory compliance in drug development.

Management Changes

Corporate Governance

Related Party Transactions

• The Master Services Agreement is with IROS, an affiliate of Group 42 Holding Ltd. and Mubadala Investment Company PJSC.
• The NuroMENA board expansion includes individuals from Quazar Investment, which will gain majority control of NuroMENA upon closing of a $50 million investment. This indicates a significant related party relationship and transaction.

Stakeholder Impact

• Shareholders: Positive impact due to strategic expansion, validation of scientific platform, accelerated clinical development, and strengthened regional governance, potentially leading to increased market value and future revenue streams.
• Patients: Potential for faster access to novel cancer treatments, particularly for CNS cancers, through accelerated clinical trials in a world-class health ecosystem.
• Employees: Potential for new opportunities and growth within the expanded regional operations.
• Partners (IROS/M42, Quazar Investment): Strengthens their position in the clinical research and healthcare investment sectors, respectively, and aligns with their strategic goals for innovation and regional leadership.
• Regulatory Authorities: The filing emphasizes compliance with Good Clinical Practice guidelines and applicable UAE and FDA regulations, indicating a commitment to high standards.

Next Steps

• Transfer the MSA to NeOnc's controlled UAE subsidiary (NuroCure) once its incorporation is complete.
• Execute specific work orders under the MSA for individual projects or studies.
• Conduct the multi-site, randomized Phase 2b/3 study for Intranasal NEO100 in the UAE.
• Finalize the $50 million investment and execution of the change of control with Quazar Investment for NuroMENA.
• Continue advancing NEO100 and NEO212 therapeutics through Phase II clinical trials under FDA Fast-Track and IND status.

Key Dates

Recommendation

This filing represents a significant positive catalyst for NeOnc Technologies. The Master Services Agreement with IROS, an M42 affiliate, provides access to a robust, AI-powered healthcare ecosystem in the UAE, which is crucial for accelerating clinical trials for CNS therapies. This partnership not only validates NeOnc's scientific platform but also establishes a strong operational foundation in a strategically important region. The concurrent expansion of the NuroMENA board with Quazar Investment partners, linked to a $50 million investment, further strengthens governance and financial backing for regional growth. For a clinical-stage biopharmaceutical company, securing such partnerships and funding for accelerated clinical development is a strong indicator of future potential and significantly de-risks the development pathway, making it a compelling "strong buy" for investors.

Keywords

Biopharmaceutical, Clinical Trials, CNS Cancers, Glioblastoma, Astrocytoma, Neuro-oncology, UAE Healthcare, Contract Research Organization (CRO), M42 Group, Quazar Investment, NuroMENA, NEO100, SEC Filing, Biotech, Drug Development